Biogen Inc. has announced that Susan H. Alexander, its Executive Vice President and Chief Legal Officer, will retire at the end of May 2026, concluding a two-decade tenure with the biotechnology firm. Alexander joined Biogen in 2006, initially serving as Executive Vice President and General Counsel before assuming her current role. Prior to her time at Biogen, she held senior legal positions at PAREXEL International Corporation and IONA Technologies, and was a partner at the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne. She earned her B.A. from Wellesley College and her J.D. from Boston University School of Law. ([biogen.com](https://www.biogen.com/company/leadership/alexander-susan.html?utm_source=openai))
During her tenure, Alexander played a pivotal role in navigating Biogen through complex legal landscapes, including regulatory challenges and intellectual property matters. Her leadership contributed to the company’s strategic initiatives and compliance programs, reinforcing Biogen’s commitment to ethical practices and corporate governance.
Biogen has initiated a search for Alexander’s successor, aiming to ensure a seamless transition in its legal leadership. This move is part of a broader series of executive changes within the company. In October 2024, Biogen announced that Michael McDonnell, Executive Vice President and Chief Financial Officer, would retire on February 28, 2025, with Robin Kramer, the current Chief Accounting Officer, set to succeed him. ([investors.biogen.com](https://investors.biogen.com/news-releases/news-release-details/michael-mcdonnell-executive-vice-president-and-chief-financial?utm_source=openai))
Additionally, in September 2023, Biogen appointed Jane Grogan, Ph.D., as Executive Vice President and Head of Research, signaling the company’s intent to diversify its research efforts beyond neuroscience. ([globenewswire.com](https://www.globenewswire.com/news-release/2023/09/06/2738268/0/en/Biogen-Appoints-Jane-Grogan-as-Head-of-Research.html?utm_source=openai))
These leadership transitions reflect Biogen’s ongoing efforts to adapt to the evolving biopharmaceutical landscape and to position the company for sustained growth and innovation.